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Abstract
Background: There is no standardized international model for specialist lymphedema services, which covers
the types of lymphedema treated and the treatments provided. The aim of this study was to provide a profile of
patients attending specialist lymphedema services in different countries to explore similarities and differences.
Methods and Results: The LIMPRINT core tool was used in specialist lymphedema services in the United
Kingdom, France, Italy, and Turkey. Services in Turkey saw a slightly younger age group, with a higher proportion
of female patients reflecting a particular focus on breast cancer-related lymphedema. There were higher levels of
obesity and restricted mobility in patients in the United Kingdom compared with other countries. Italy and France
saw the highest percentage of patients with primary lymphedema. Diabetes was a common comorbidity in the United
Kingdom and Turkey. The United Kingdom saw the largest number of patients with lower limb lymphedema.
Conclusions: The results show a wide range of complexity of patients treated in specialist lymphedema
services. Some of the differences between countries may reflect different stages in the evolution of specialist
lymphedema services, rather than a true difference in prevalence, with those with ‘‘younger’’ services treating a
high proportion of patients with cancer and those with more established services treating a wider range of
different types of lymphedema, including more elderly people with multiple comorbidities.
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Introduction
In many countries, specialist lymphedema services havebeen developed to treat patients with chronic edema.
However, there is no standardized service model, which
covers the types of chronic edema treated, the diagnostic tests
available, the range of treatments offered, and the expertise
and background of specialist professionals, who make up the
multidisciplinary team.
In a number of services, the types of chronic edema treated
have evolved over the years. For example, in the United
Kingdom, specialist services in the past were largely focused
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on treating patients with cancer-related lymphedema. Some
were based in specialist palliative care services, whereas
others developed in specialist medical areas such as derma-
tology. However, with time, the types of patients treated by
many of the services have changed to include primary lym-
phedema and secondary lymphedema, with a wide range of
non-cancer causes including immobility and neurological
conditions. A number of services now treat both adults and
children. As a result of this, the proportion of patients with
cancer-related lymphedema has reduced in these services, as
the total number of patients seen has increased.
To facilitate a better understanding of these issues and to
enable governments to provide appropriate specialist services
for people with chronic edema, a profile of patients attending
specialist lymphedema services in different countries has
been obtained by using the LIMPRINT methodology. With
the wealth of data obtained from such an approach, it is also
possible to begin to look at specific features in elements of the
population served, for example, the prevalence of cellulitis in
people with primary lymphedema compared with those with
secondary chronic edema.
Materials and Methods
Data using the LIMPRINT core tool were obtained from
clinical records of all patients currently attending nine specific
specialist lymphedema services in four different countries—
the United Kingdom, France, Italy, and Turkey. All services
checked the accuracy of ‘‘current’’ patients by removing those
who had died or had been discharged from the total.
All patients had already been assessed by a specialist team
to define the correct classification of chronic edema. Data
queries were checked with service leads and lymphedema
therapists. As in other LIMPRINT studies, the term ‘‘sec-
ondary lymphedema’’ is used to cover all types of chronic
edema other than primary lymphedema.
The data were analyzed to provide a description of the total
sample, comparisons of patient profiles between countries
and between types of chronic edema. Comparisons between
countries and types of chronic edema were analyzed by Chi-
squared tests or Fisher’s exact test, where appropriate.
Results
Combined data from all services
Total number of patients. A total of 8140 clinical records
were assessed in 9 services in 4 countries. Table 1 shows the
distribution of patients across the services and countries.
Distribution of patients by age and gender. The distri-
bution of patients by age and gender is shown in Figure 1. The
distribution of men and women was similar for all age
groups; however, there was a high percentage (79%) of wo-
men in the sample. Only a very small percentage of patients
were less than the age of 15 years (n= 68, 0.84%).
Body mass index. In total, 34.5% of patients were obese
(body mass index [BMI]= 30–39.9) and 18.4% were morbidly
obese (BMI >40). The BMI of 18.5–29.9 includes normal
weight (18.5–24.9) and overweight (25–29.9). Only 1.1% of
patients were considered ‘‘underweight’’ (BMI <18.5).
Mobility. Lower limb mobility was restricted (i.e., walked
with aid, chair bound, or bed-bound) in 40.8% of those with
leg lymphedema, and upper limb mobility was restricted in
27.4% of those with arm lymphedema (Fig. 2).
Cause of chronic edema and comorbidities. A total of
17.5% of patients had primary lymphedema whereas 82.5% had
secondary lymphedema. Of those with secondary disease, can-
cer was the cause in 37.1%. Of the cancer patients, the treatment
was the cause of swelling in 95.2%, with metastatic disease
accounting for 6.3%. In 60 patients, both cancer treatment and
metastatic disease were considered to cause the swelling.
Table 2 shows the factors considered important in the
cause of chronic secondary edema. An individual patient may
have more than one contributory cause. Comorbidities were
common, with diabetes being present in 14.3%, heart disease
in 10.3%, and neurological disorders in 5.9% of the total
patient group.
Table 1. Distribution of Patients by Service
and Country
Country Service 1 Service 2 Service 3 Total
United Kingdom 3223 1636 801 5660
France 303 282 — 585
Italy 729 690 — 1419
Turkey 402 74 — 476
FIG. 1. Age and gender.
FIG. 2. Mobility in lower and upper limbs.
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Duration of swelling. The duration of swelling at the time
of assessment is shown in Table 3. More than half (55%) of
the patients had had their edema for more than 5 years.
History of cellulitis. In all, 2821 (34.7%) of patients had
had at least 1 episode of cellulitis in the past and 1091
(13.4%) had had at least 1 episode within the past year. Of
those who had had cellulitis in the past year, 686 (62.9%) had
had 1 episode, 253 (23.2%) had had 2 episodes, and 152
(13.9%) had had 3 episodes or more within the past year.
In the previous year, 255 (23.4%) of the patients with an
infection were admitted to hospital to manage their cellulitis,
of whom 197 (77.2%) were admitted once, 33 (12.9%) twice,
and 15 (5.9%) more than twice.
Site of swelling and presence of wound. Of the 8140
patients, 7842 (96.3%) had an area of swelling recorded. Of
these, 5711 (72.8%) of patients had lower limb edema, 2184
(27.9%) upper limb edema, and 1042 (13.3%) midline ede-
ma. Some patients had more than one site of edema.
In total, 543 out of 7842 (6.9%) of patients had non-
surgical-associated wounds, though the prevalence of a
wound varied greatly between countries (1.7%–7.82%).
Comparison by country
Age profile by country. The age profile of patients seen by
lymphedema services in each country is compared in
Figure 3. The Turkish services saw patients with a slightly
younger age group than the other countries, whereas the UK
services saw a larger number of older patients, particularly
those more than 75 years of age.
Gender profile by country. Of all the patients seen by
Turkish specialist services, 95.2% were female compared
with 76.1% in the United Kingdom (Fig. 4).
Levels of obesity by country. There were higher levels of
both obese (39.7%) and morbidly obese patients (24.9%) in
the United Kingdom compared with other countries. The
lowest levels of obesity were found in Italy, with obese pa-
tients representing 17.0% of the total and morbidly obese
representing 0.1% (Fig. 5).
Mobility. More patients had restricted mobility in the
United Kingdom compared with the other countries, with
only 51% of those with lower limb lymphedema being able to
walk unaided compared with more than 80% in the other
countries (Fig. 6).
Causes of chronic edema. Italy and France had higher
numbers of patients with primary lymphedema (29.7% and
36.6%) compared with just 8.8% in Turkey. Of the secondary
group, cancer-related lymphedema represented around 80%
of those seen in France and Turkey but around 34% of those
seen in the United Kingdom. Conversely, non-cancer-related
secondary lymphedema represented about 66% of those seen
in the UK specialist services compared with just 15% of those
seen in France and Turkey ( p < 0.001) (Fig. 7).
Comorbidities. Diabetes was present more frequently in
patients seen in the United Kingdom and Turkey (17.1 and
17.4%, respectively) compared with 3.8% in France and
6.1% in Turkey. Heart disease was higher in the UK group
(12.1%) compared with all other countries (all <8%). Neu-
rological diseases were also more common in patients seen
by UK services (7.7%) compared with the other countries (all
<3%; p< 0.001) (Fig. 8).
Table 2. Factors Contributing
to Secondary Edema
Factor %
Cancer treatment 34.8
Metastatic cancer 2.3
Venous disease 19.6
Immobility 16.3
Obesity 14.3
Other 25.9
Table 3. Duration of Swelling
%
<6 Months 4.8
6–12 Months 6.3
1–2 Years 11.4
2–5 Years 22.6
5–10 Years 23.5
>10 Years 31.5
FIG. 3. Age profile given by country.
FIG. 4. Comparison of gender by country.
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Duration of chronic edema. Italy and Turkey saw patients
with a shorter duration of chronic edema than France and the
United Kingdom. In France and the United Kingdom, more
than 30% of patients had had chronic edema for more than 10
years (Fig. 9).
Site of swelling and presence of wounds. Turkey saw the
greatest number of patients with upper limb lymphedema
(68.7%), whereas the United Kingdom saw the greatest
number with lower limb lymphedema (78.9%) (Fig. 10).
Non-surgical wounds were present more frequently in Italy
(7.82%) and the United Kingdom (7.37%), with the other
countries having fewer than 3% with wounds.
Comparison of some of the features of primary
and secondary lymphedema
Episodes of cellulitis. A history of cellulitis was reported
in 32.2% of those with primary lymphedema compared with
35.1% of those with secondary lymphedema.
The presence of wounds. Wounds were seen in 7.66% of
those with secondary lymphedema compared with only
3.22% of those with primary lymphedema across all services
and countries ( p < 0.001).
Presence of obesity. Overall, 32.8% of those with pri-
mary lymphedema and 34.8% of those with secondary
lymphedema were obese whereas 11.2% of people with
primary lymphedema and 19.6% of those with secondary
lymphedema were morbidly obese ( p < 0.001) across all
categories.
Presence of diabetes. Of those with secondary lymphe-
dema, 15.8% had coexistent diabetes compared with 7.0% of
those with primary lymphedema ( p < 0. 001).
Discussion
These LIMPRINT data have provided a wealth of infor-
mation about patients who are currently seen in a number of
specialist services across Europe. It was already known that
there was no standard definition of what constituted a spe-
cialist service, for example, staffing, diagnostics, and treat-
ment provision, and which type of patients are seen by such a
service.
The collected data from all the services give an overall
profile of patients seen and because of the large numbers, they
can give some information about other features such as
whether there are different characteristics found in those with
primary lymphedema compared with those with secondary
chronic edema.
FIG. 5. Level of obesity.
FIG. 6. Mobility status by country.
FIG. 7. Causes of lymphedema.
FIG. 8. Medical history by country.
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Combined data from all services
This confirms the wide age range of patients seen by
specialist lymphedema services and the relatively small
number of children seen. Some specialist services do not see
children at all.
Not surprisingly, most patients seen were female. This
finding is consistent with other published prevalence data.1
Fifty-four percent of patients were obese or morbidly ob-
ese. This confirms the significant impact of obesity on
chronic edema. Managing chronic edema in this group of
patients can be challenging in that response to conventional
decongestive lymphedema therapy is often disappointing.
These data are also important to consider when planning
service provision.
Lower limb mobility was restricted in more than 1 out of 3
of those with lower limb lymphedema. Immobility can cause
lower limb lymphedema but conversely chronic edema im-
pairs mobility. The role of exercise and physiotherapy input
to specialist services is, therefore, important in managing
these patients effectively.
Of the total, 16% of patients seen in specialist services had
primary lymphedema. This may be a disproportionately high
number compared with the prevalence in the wider popula-
tion as a number of specialist services specialize in managing
patients with primary lymphedema.
Cancer and its treatment were the cause of edema in 37%
of patients. However, cancer is often considered the major
cause of lymphedema by health care providers and these
data confirm that, although an important problem, the ma-
jority of patients with chronic edema do not have cancer.
Venous disease, immobility, and obesity are significant
factors contributing to the cause of chronic swelling. Dia-
betes, heart disease, and neurological disorders were com-
mon comorbidities.
This snapshot profile has also confirmed that people at-
tending specialist services have had chronic edema for a
varied period. More than half have had swelling for more than
5 years before referral.
Cellulitis is a well-known complication of chronic edema,
and more than one third of patients in this study had had at
least one episode of cellulitis in the past.
The majority of patients (70%) had lower limb edema.
This mirrors the results of previous studies.1 In addition,
6.9% of all patients had wounds. This association has been
previously demonstrated.1
Comparison by country
There were a number of differences that emerged when the
data were analyzed by country.
The Turkish centers saw people of a slightly younger age
range than other countries, whereas the UK services saw a
large number of older patients, particularly those older than
75 years. More women were seen by the Turkish services
(95%). Of those with secondary lymphedema, cancer-related
lymphedema represented around 80% those seen in France,
Italy, and Turkey compared with around 35% in the United
Kingdom. A higher percentage of patients seen in Italy and
France had primary lymphedema (30%) compared within
Turkey and the United Kingdom (10%). More people in the
United Kingdom had restricted mobility than those in other
countries. In addition, diabetes, heart disease, and neuro-
logical disease were more common in patients seen in the
United Kingdom. Italy and Turkey saw patients with a shorter
duration of chronic edema than France and the United
Kingdom. The Turkish services saw the greatest number of
patients with upper limb lymphedema (69%), whereas UK
services saw the greatest number of patients with lower limb
lymphedema (79%).
Of the patients seen in Italy, 7.82% had wounds with a
similar proportion in the United Kingdom. The remaining
countries had fewer than 3%.
The Turkish centers are largely focused on seeing women
with breast cancer treatment-related lymphedema. Con-
versely, the UK services see large numbers of patients with
chronic secondary edema related to a wide range of other
conditions, which occur in more elderly populations. Dia-
betes seemed to be disproportionately common in the Turkish
lymphedema services, but this is consistent with a higher
prevalence of diabetes in Turkey’s general population than in
the other countries represented here. According to a WHO
report, the prevalence of diabetes in Turkey is 13.2% com-
pared with 7.7% in the United Kingdom, 8.5% in Italy, and
8.0% in France.2
The United Kingdom had the highest proportion of people
with obesity and morbid obesity. This fits with OECD figures,
which show a prevalence of obesity in 2017 as 10% in Italy,
15% in France, 22% in Turkey, and 27% in the United
Kingdom.3
The differences in patients seen between countries may, in
part, not only reflect the different prevalence of other con-
ditions such as obesity and diabetes but also probably reflect
FIG. 9. Swelling duration by country.
FIG. 10. Site of swelling and presence of a wound by
country.
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the types of patients referred to and seen by the different
specialist services. Historically, in the United Kingdom,
many developing lymphedema services in the 1980s and
1990s focused on treating people with cancer.
However, subsequently, UK services began to see more
and more patients with non-cancer-related chronic edema
and this is reflected in the UK figures seen in this study. This
probably reflects more closely the range of different types of
chronic edema present in community populations. Countries
such as Turkey may be undergoing a similar evolutionary
process, as it will be increasingly recognized that those with
cancer-related lymphedema represent only a minority of
people who have chronic edema. However, it is possible that
patients with non-cancer-related edema may be seen by other
services not taking part in this study.
Comparison of features of primary
and secondary lymphedema
This large dataset has enabled an analysis that can compare
problems associated with primary and secondary lymphe-
dema. A history of cellulitis was seen in around 35% of both
those with primary lymphedema and those with secondary
lymphedema, suggesting that there is little difference be-
tween the two types, and that patients with both primary and
secondary lymphedema should be advised about the risk of
cellulitis and how to manage it. Wounds were seen more
frequently in those with secondary lymphedema. This is
consistent with previous data.1
Interestingly, the percentage of people with primary and
secondary lymphedema who were obese was similar, al-
though morbid obesity was present in 19.6% of those with
secondary lymphedema compared with 11.2% of those with
primary lymphedema. This stresses the importance of obesity
not only as a cause of chronic edema but also as a contribu-
tory factor in making lymphedema worse.4 Diabetes was
more common in those with secondary lymphedema than
those with primary lymphedema. This could, of course, be
related to the increased risk of type II diabetes in obesity.
Although the methods adopted for the LIMPRINT study
and the training of those carrying out the work should facil-
itate a consistent approach across countries, it is possible that
there could be some inconsistencies in the diagnosis of pri-
mary lymphedema. Primary lymphedema is currently con-
sidered a genetic condition and is often diagnosed by using
the St George’s algorithm.5 In the past, however, it was
considered a diagnosis of exclusion and, therefore, if no
secondary cause of chronic edema was found, the condition
was labeled as ‘‘primary.’’ However, it is not clear whether
these factors may have influenced the diagnosis of primary
lymphedema here.
Conclusions
The data reported here show the wide range of complexity
of patients seen in specialist lymphedema services. This
needs to be reflected in the skills of the multidisciplinary team
providing the service. The data could, therefore, be useful to
inform the development of a service specification for spe-
cialist chronic edema services.
Some of the differences between countries may reflect dif-
ferent stages in the evolution of specialist lymphedema ser-
vices rather than big differences in the prevalence of different
types of chronic edema in the communities served by the
services. Population-based studies would help give an answer
to this but are extremely difficult and costly to carry out.
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